Pharmacokinetics of deflazacort in rabbits after intravenous and oral administration and its interaction with erythromycin

The pharmacokinetic of deflazacort after intravenous and oral administration and the effect of erythromycin on the disposition of deflazacort in rabbits were investigated. A parallel study was carried out in twelve rabbits. The plasma concentration–time profiles of deflazacort were determined after...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of veterinary pharmacology and therapeutics 2018-02, Vol.41 (1), p.e10-e15
Hauptverfasser: Escudero, A. I., Marín, P., Cárceles, C. M., Escudero, E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e15
container_issue 1
container_start_page e10
container_title Journal of veterinary pharmacology and therapeutics
container_volume 41
creator Escudero, A. I.
Marín, P.
Cárceles, C. M.
Escudero, E.
description The pharmacokinetic of deflazacort after intravenous and oral administration and the effect of erythromycin on the disposition of deflazacort in rabbits were investigated. A parallel study was carried out in twelve rabbits. The plasma concentration–time profiles of deflazacort were determined after intravenous and oral administration of single dosages of 5 mg/kg in the presence and absence (baseline) of multiple dose erythromycin regimens. Plasma concentrations of 21‐desacetyldeflazacort were determined by HPLC. Plasma concentration–time curves were analysed by compartmental pharmacokinetic and noncompartmental methods. The t½λz values following intravenous and oral administration were 3.67 and 4.96 hr, respectively. The apparent volume of distribution at steady‐state (Vss) was 4.08 ± 0.31 L/kg, this value indicates that deflazacort is widely distributed into the extravascular tissues. Moreover, bioavailability after oral administration of deflazacort (F = 87.48%) was high. Pharmacokinetic analysis after both routes of administration revealed a significant reduction in total body clearance, a significant increase in mean residence time, half‐life and plasma concentrations of the steroid in the presence of multiple dose erythromycin. The results indicated the influence of the erythromycin on deflazacort disposition, which is consistent with a pharmacokinetic‐type interaction in the elimination of the drug from the body. Moreover, this interaction should be considered to avoid adverse effects when using both drugs concomitantly.
doi_str_mv 10.1111/jvp.12442
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1923107934</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1923107934</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3512-653cb1878ea2ad8e13cc62d01245b9b663e602e8efc8bf4b6bec6454680787f13</originalsourceid><addsrcrecordid>eNp1kMlOwzAURS0EoqWw4AdQlrBI6yFx3CWqGFWJLoBtZDsvqkuGYrut0q_HHWDH21g6Pu9K7yJ0TfCQhBkt1sshoUlCT1CfMJ7GVIj0FPUxSXCcZYL10IVzC4wxE4Scox4VWUI4F320nc2lraVuv0wD3mgXtWVUQFnJbYDWR6aJrFTKeBfJ0oMNwFu5hqZdBdIUUWtlFcmiNo1x4cebttnz3UZwwUq9Zxvj5xHYzs9tW3faNJforJSVg6vjO0Afjw_vk-d4-vb0MrmfxpqlhMY8ZVoRkQmQVBYCCNOa0wKHg1M1Vpwz4JiCgFILVSaKK9A8SRMucCaykrABuj3kLm37vQLn89o4DVUlGwhH5GRMGcHZmCVBvTuo2rbOWSjzpTW1tF1OcL6rOg9V5_uqg3tzjF2pGoo_87fbIIwOwsZU0P2flL9-zg6RP5WMi1U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1923107934</pqid></control><display><type>article</type><title>Pharmacokinetics of deflazacort in rabbits after intravenous and oral administration and its interaction with erythromycin</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Escudero, A. I. ; Marín, P. ; Cárceles, C. M. ; Escudero, E.</creator><creatorcontrib>Escudero, A. I. ; Marín, P. ; Cárceles, C. M. ; Escudero, E.</creatorcontrib><description>The pharmacokinetic of deflazacort after intravenous and oral administration and the effect of erythromycin on the disposition of deflazacort in rabbits were investigated. A parallel study was carried out in twelve rabbits. The plasma concentration–time profiles of deflazacort were determined after intravenous and oral administration of single dosages of 5 mg/kg in the presence and absence (baseline) of multiple dose erythromycin regimens. Plasma concentrations of 21‐desacetyldeflazacort were determined by HPLC. Plasma concentration–time curves were analysed by compartmental pharmacokinetic and noncompartmental methods. The t½λz values following intravenous and oral administration were 3.67 and 4.96 hr, respectively. The apparent volume of distribution at steady‐state (Vss) was 4.08 ± 0.31 L/kg, this value indicates that deflazacort is widely distributed into the extravascular tissues. Moreover, bioavailability after oral administration of deflazacort (F = 87.48%) was high. Pharmacokinetic analysis after both routes of administration revealed a significant reduction in total body clearance, a significant increase in mean residence time, half‐life and plasma concentrations of the steroid in the presence of multiple dose erythromycin. The results indicated the influence of the erythromycin on deflazacort disposition, which is consistent with a pharmacokinetic‐type interaction in the elimination of the drug from the body. Moreover, this interaction should be considered to avoid adverse effects when using both drugs concomitantly.</description><identifier>ISSN: 0140-7783</identifier><identifier>EISSN: 1365-2885</identifier><identifier>DOI: 10.1111/jvp.12442</identifier><identifier>PMID: 28741668</identifier><language>eng</language><publisher>England</publisher><subject>Administration, Oral ; Animals ; deflazacort ; Dose-Response Relationship, Drug ; erythromycin ; Erythromycin - pharmacokinetics ; Half-Life ; Injections, Intravenous ; interaction ; pharmacokinetics ; Pregnenediones - administration &amp; dosage ; Pregnenediones - antagonists &amp; inhibitors ; Pregnenediones - blood ; Pregnenediones - pharmacokinetics ; Rabbits</subject><ispartof>Journal of veterinary pharmacology and therapeutics, 2018-02, Vol.41 (1), p.e10-e15</ispartof><rights>2017 John Wiley &amp; Sons Ltd</rights><rights>2017 John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3512-653cb1878ea2ad8e13cc62d01245b9b663e602e8efc8bf4b6bec6454680787f13</citedby><cites>FETCH-LOGICAL-c3512-653cb1878ea2ad8e13cc62d01245b9b663e602e8efc8bf4b6bec6454680787f13</cites><orcidid>0000-0003-4849-4452</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjvp.12442$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjvp.12442$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28741668$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Escudero, A. I.</creatorcontrib><creatorcontrib>Marín, P.</creatorcontrib><creatorcontrib>Cárceles, C. M.</creatorcontrib><creatorcontrib>Escudero, E.</creatorcontrib><title>Pharmacokinetics of deflazacort in rabbits after intravenous and oral administration and its interaction with erythromycin</title><title>Journal of veterinary pharmacology and therapeutics</title><addtitle>J Vet Pharmacol Ther</addtitle><description>The pharmacokinetic of deflazacort after intravenous and oral administration and the effect of erythromycin on the disposition of deflazacort in rabbits were investigated. A parallel study was carried out in twelve rabbits. The plasma concentration–time profiles of deflazacort were determined after intravenous and oral administration of single dosages of 5 mg/kg in the presence and absence (baseline) of multiple dose erythromycin regimens. Plasma concentrations of 21‐desacetyldeflazacort were determined by HPLC. Plasma concentration–time curves were analysed by compartmental pharmacokinetic and noncompartmental methods. The t½λz values following intravenous and oral administration were 3.67 and 4.96 hr, respectively. The apparent volume of distribution at steady‐state (Vss) was 4.08 ± 0.31 L/kg, this value indicates that deflazacort is widely distributed into the extravascular tissues. Moreover, bioavailability after oral administration of deflazacort (F = 87.48%) was high. Pharmacokinetic analysis after both routes of administration revealed a significant reduction in total body clearance, a significant increase in mean residence time, half‐life and plasma concentrations of the steroid in the presence of multiple dose erythromycin. The results indicated the influence of the erythromycin on deflazacort disposition, which is consistent with a pharmacokinetic‐type interaction in the elimination of the drug from the body. Moreover, this interaction should be considered to avoid adverse effects when using both drugs concomitantly.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>deflazacort</subject><subject>Dose-Response Relationship, Drug</subject><subject>erythromycin</subject><subject>Erythromycin - pharmacokinetics</subject><subject>Half-Life</subject><subject>Injections, Intravenous</subject><subject>interaction</subject><subject>pharmacokinetics</subject><subject>Pregnenediones - administration &amp; dosage</subject><subject>Pregnenediones - antagonists &amp; inhibitors</subject><subject>Pregnenediones - blood</subject><subject>Pregnenediones - pharmacokinetics</subject><subject>Rabbits</subject><issn>0140-7783</issn><issn>1365-2885</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMlOwzAURS0EoqWw4AdQlrBI6yFx3CWqGFWJLoBtZDsvqkuGYrut0q_HHWDH21g6Pu9K7yJ0TfCQhBkt1sshoUlCT1CfMJ7GVIj0FPUxSXCcZYL10IVzC4wxE4Scox4VWUI4F320nc2lraVuv0wD3mgXtWVUQFnJbYDWR6aJrFTKeBfJ0oMNwFu5hqZdBdIUUWtlFcmiNo1x4cebttnz3UZwwUq9Zxvj5xHYzs9tW3faNJforJSVg6vjO0Afjw_vk-d4-vb0MrmfxpqlhMY8ZVoRkQmQVBYCCNOa0wKHg1M1Vpwz4JiCgFILVSaKK9A8SRMucCaykrABuj3kLm37vQLn89o4DVUlGwhH5GRMGcHZmCVBvTuo2rbOWSjzpTW1tF1OcL6rOg9V5_uqg3tzjF2pGoo_87fbIIwOwsZU0P2flL9-zg6RP5WMi1U</recordid><startdate>201802</startdate><enddate>201802</enddate><creator>Escudero, A. I.</creator><creator>Marín, P.</creator><creator>Cárceles, C. M.</creator><creator>Escudero, E.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4849-4452</orcidid></search><sort><creationdate>201802</creationdate><title>Pharmacokinetics of deflazacort in rabbits after intravenous and oral administration and its interaction with erythromycin</title><author>Escudero, A. I. ; Marín, P. ; Cárceles, C. M. ; Escudero, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3512-653cb1878ea2ad8e13cc62d01245b9b663e602e8efc8bf4b6bec6454680787f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>deflazacort</topic><topic>Dose-Response Relationship, Drug</topic><topic>erythromycin</topic><topic>Erythromycin - pharmacokinetics</topic><topic>Half-Life</topic><topic>Injections, Intravenous</topic><topic>interaction</topic><topic>pharmacokinetics</topic><topic>Pregnenediones - administration &amp; dosage</topic><topic>Pregnenediones - antagonists &amp; inhibitors</topic><topic>Pregnenediones - blood</topic><topic>Pregnenediones - pharmacokinetics</topic><topic>Rabbits</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Escudero, A. I.</creatorcontrib><creatorcontrib>Marín, P.</creatorcontrib><creatorcontrib>Cárceles, C. M.</creatorcontrib><creatorcontrib>Escudero, E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of veterinary pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Escudero, A. I.</au><au>Marín, P.</au><au>Cárceles, C. M.</au><au>Escudero, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics of deflazacort in rabbits after intravenous and oral administration and its interaction with erythromycin</atitle><jtitle>Journal of veterinary pharmacology and therapeutics</jtitle><addtitle>J Vet Pharmacol Ther</addtitle><date>2018-02</date><risdate>2018</risdate><volume>41</volume><issue>1</issue><spage>e10</spage><epage>e15</epage><pages>e10-e15</pages><issn>0140-7783</issn><eissn>1365-2885</eissn><abstract>The pharmacokinetic of deflazacort after intravenous and oral administration and the effect of erythromycin on the disposition of deflazacort in rabbits were investigated. A parallel study was carried out in twelve rabbits. The plasma concentration–time profiles of deflazacort were determined after intravenous and oral administration of single dosages of 5 mg/kg in the presence and absence (baseline) of multiple dose erythromycin regimens. Plasma concentrations of 21‐desacetyldeflazacort were determined by HPLC. Plasma concentration–time curves were analysed by compartmental pharmacokinetic and noncompartmental methods. The t½λz values following intravenous and oral administration were 3.67 and 4.96 hr, respectively. The apparent volume of distribution at steady‐state (Vss) was 4.08 ± 0.31 L/kg, this value indicates that deflazacort is widely distributed into the extravascular tissues. Moreover, bioavailability after oral administration of deflazacort (F = 87.48%) was high. Pharmacokinetic analysis after both routes of administration revealed a significant reduction in total body clearance, a significant increase in mean residence time, half‐life and plasma concentrations of the steroid in the presence of multiple dose erythromycin. The results indicated the influence of the erythromycin on deflazacort disposition, which is consistent with a pharmacokinetic‐type interaction in the elimination of the drug from the body. Moreover, this interaction should be considered to avoid adverse effects when using both drugs concomitantly.</abstract><cop>England</cop><pmid>28741668</pmid><doi>10.1111/jvp.12442</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4849-4452</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0140-7783
ispartof Journal of veterinary pharmacology and therapeutics, 2018-02, Vol.41 (1), p.e10-e15
issn 0140-7783
1365-2885
language eng
recordid cdi_proquest_miscellaneous_1923107934
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Administration, Oral
Animals
deflazacort
Dose-Response Relationship, Drug
erythromycin
Erythromycin - pharmacokinetics
Half-Life
Injections, Intravenous
interaction
pharmacokinetics
Pregnenediones - administration & dosage
Pregnenediones - antagonists & inhibitors
Pregnenediones - blood
Pregnenediones - pharmacokinetics
Rabbits
title Pharmacokinetics of deflazacort in rabbits after intravenous and oral administration and its interaction with erythromycin
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T19%3A55%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20of%20deflazacort%20in%20rabbits%20after%20intravenous%20and%20oral%20administration%20and%20its%20interaction%20with%20erythromycin&rft.jtitle=Journal%20of%20veterinary%20pharmacology%20and%20therapeutics&rft.au=Escudero,%20A.%20I.&rft.date=2018-02&rft.volume=41&rft.issue=1&rft.spage=e10&rft.epage=e15&rft.pages=e10-e15&rft.issn=0140-7783&rft.eissn=1365-2885&rft_id=info:doi/10.1111/jvp.12442&rft_dat=%3Cproquest_cross%3E1923107934%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1923107934&rft_id=info:pmid/28741668&rfr_iscdi=true